JP2021534158A5 - - Google Patents
Info
- Publication number
- JP2021534158A5 JP2021534158A5 JP2021507737A JP2021507737A JP2021534158A5 JP 2021534158 A5 JP2021534158 A5 JP 2021534158A5 JP 2021507737 A JP2021507737 A JP 2021507737A JP 2021507737 A JP2021507737 A JP 2021507737A JP 2021534158 A5 JP2021534158 A5 JP 2021534158A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- independently
- substituted
- pharmaceutical composition
- independently selected
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862764900P | 2018-08-16 | 2018-08-16 | |
| US62/764,900 | 2018-08-16 | ||
| PCT/US2019/046592 WO2020037092A1 (en) | 2018-08-16 | 2019-08-15 | Imidazo[4,5-c]quinoline derived nlrp3-modulators |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021534158A JP2021534158A (ja) | 2021-12-09 |
| JPWO2020037092A5 JPWO2020037092A5 (https=) | 2022-08-01 |
| JP2021534158A5 true JP2021534158A5 (https=) | 2022-08-01 |
| JP7433291B2 JP7433291B2 (ja) | 2024-02-19 |
Family
ID=67777458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507737A Active JP7433291B2 (ja) | 2018-08-16 | 2019-08-15 | イミダゾ［４，５－ｃ］キノリン誘導体のＮＬＲＰ３モジュレーター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12024513B2 (https=) |
| EP (1) | EP3837015B1 (https=) |
| JP (1) | JP7433291B2 (https=) |
| KR (1) | KR102817037B1 (https=) |
| CN (1) | CN112996567A (https=) |
| ES (1) | ES2974964T3 (https=) |
| WO (1) | WO2020037092A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112888677A (zh) | 2018-08-16 | 2021-06-01 | 先天肿瘤免疫公司 | 被取代的4-氨基-1H-咪唑并[4,5-c]喹啉化合物及其改进的制备方法 |
| US20210269434A1 (en) * | 2020-01-10 | 2021-09-02 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| MX2024000357A (es) | 2021-07-07 | 2024-02-12 | Incyte Corp | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). |
| US12600717B2 (en) | 2021-07-14 | 2026-04-14 | Incyte Corporation | Tricyclic compounds as inhibitors of KRAS |
| US12441742B2 (en) | 2021-08-31 | 2025-10-14 | Incyte Corporation | Naphthyridine compounds as inhibitors of KRAS |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| CA3234375A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| MXPA05006740A (es) | 2002-12-20 | 2005-10-05 | 3M Innovative Properties Co | Imidazoquinolinas arilo-sustituidas. |
| US20080015184A1 (en) | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
| US20070259881A1 (en) | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011144622A1 (en) * | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | 1h - imidazo [4, 5 - c] quinolines |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2015095780A1 (en) | 2013-12-20 | 2015-06-25 | The University Of Kansas | Toll-like receptor 8 agonists |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| KR20180040706A (ko) | 2015-09-01 | 2018-04-20 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도 |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| KR102161364B1 (ko) * | 2015-09-14 | 2020-09-29 | 화이자 인코포레이티드 | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CN111491361B (zh) | 2016-02-02 | 2023-10-24 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| CA3021349A1 (en) | 2016-04-19 | 2017-10-26 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
-
2019
- 2019-08-15 JP JP2021507737A patent/JP7433291B2/ja active Active
- 2019-08-15 WO PCT/US2019/046592 patent/WO2020037092A1/en not_active Ceased
- 2019-08-15 ES ES19759842T patent/ES2974964T3/es active Active
- 2019-08-15 EP EP19759842.8A patent/EP3837015B1/en active Active
- 2019-08-15 CN CN201980068466.6A patent/CN112996567A/zh active Pending
- 2019-08-15 KR KR1020217007430A patent/KR102817037B1/ko active Active
- 2019-08-15 US US17/267,516 patent/US12024513B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534158A5 (https=) | ||
| JP2021534168A5 (https=) | ||
| JP2021522249A5 (https=) | ||
| JP2020125349A5 (https=) | ||
| JP2020508302A5 (https=) | ||
| Guo et al. | Interleukin-6 signaling pathway in targeted therapy for cancer | |
| RU2016108667A (ru) | Комбинированная терапия для лечения рака | |
| JP2020517616A5 (https=) | ||
| JPWO2019209896A5 (https=) | ||
| RU2007110480A (ru) | Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы | |
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| JP2018062523A5 (https=) | ||
| JP2019535746A5 (https=) | ||
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| JP2022517109A5 (https=) | ||
| RU2015121424A (ru) | Комбинированная терапия | |
| JP2016528162A5 (https=) | ||
| JP2015536986A5 (https=) | ||
| JP2014528464A5 (https=) | ||
| JPWO2020037091A5 (https=) | ||
| JP2014518544A5 (https=) | ||
| RU2020113749A (ru) | Аналоги таиланстатина | |
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| JPWO2020037092A5 (https=) |